Severe acute respiratory syndrome-related coronavirus

Diazyme Laboratories, Inc. Receives FDA EUA for COVID-19 Antibody Test

Retrieved on: 
Thursday, July 9, 2020
Medical specialties, Medicine, Branches of biology, Blood tests, Immunologic tests, Epidemiology, Immunology, Emergency Use Authorization, Food and Drug Administration, Severe acute respiratory syndrome-related coronavirus, Serology, Clinical Laboratory Improvement Amendments

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Diazyme announces receiving FDA Emergency Use Authorization (EUA) letter for the Diazyme DZ-Lite SARS-CoV-2 IgG CLIA test.

Key Points: 
  • SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Diazyme announces receiving FDA Emergency Use Authorization (EUA) letter for the Diazyme DZ-Lite SARS-CoV-2 IgG CLIA test.
  • The Diazyme IgG test is run on the fully automated DZ-Lite 3000 Plus chemiluminescence analyzer.
  • Diazyme has been at the forefront of the development effort to bring timely, high quality COVID-19 serology (antibody) tests during the public health emergency.
  • The fully automated Diazyme DZ-Lite SARS-CoV-2 IgG test exceeds sensitivity and specificity requirements for laboratory run serology tests.

Absolute Antibody and University of Zurich Collaborate to Offer Synthetic Nanobodies Against SARS-CoV-2 Receptor Binding Domain

Retrieved on: 
Wednesday, July 8, 2020
Medical specialties, Immunology, Medicine, Branches of biology, Immune system, Animal virology, Coronaviridae, Single-domain antibody, Severe acute respiratory syndrome-related coronavirus, Coronavirus, Antibody, Monoclonal antibody

REDCAR, U.K., July 8, 2020 /PRNewswire-PRWeb/ -- Absolute Antibody Ltd. , an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.

Key Points: 
  • REDCAR, U.K., July 8, 2020 /PRNewswire-PRWeb/ -- Absolute Antibody Ltd. , an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.
  • The laboratory of Markus Seeger at University of Zurich developed a rapid in vitro selection platform to generate synthetic nanobodies, known as sybodies, against the receptor binding domain (RBD) of SARS-CoV-2.
  • Absolute Antibody recombinantly produces the SARS-CoV-2 synthetic nanobodies for ensured batch-to-batch reproducibility, high purity and low endotoxin levels.
  • In addition, Absolute Antibody has used antibody engineering to fuse the nanobodies to Fc domains in different species, isotypes and subtypes.

LI-COR Near-Infrared Assays and Technology Offer Insight to Coronavirus Researchers

Retrieved on: 
Tuesday, July 7, 2020
Viruses, Zoonoses, Natural sciences, Laboratory techniques, Microbiology, Virology, Cytopathic effect, Severe acute respiratory syndrome-related coronavirus, Assay, LI-COR Biosciences, Severe acute respiratory syndrome

Key to this process are quantifiable assays that provide robust data for all aspects of research.

Key Points: 
  • Key to this process are quantifiable assays that provide robust data for all aspects of research.
  • LI-CORBiosciences continues to support virology researchers with products, tools, and services to better understand SARS-CoV-2 and other viruses.
  • Traditionally, infectivity of viruses that exhibit cytopathic effect (CPE) has been characterized using plaque assays.
  • From academic discovery through preclinical validation, whether characterizing a pathway or validating a therapeutic candidate, LI-COR technology helps move research through the development process.

Proven Pharma Named Exclusive Distributor of the Clungene® SARS-CoV-2 IgG/IgM Rapid Serology Test

Retrieved on: 
Tuesday, July 7, 2020
Emergency Use Authorization, Health, Food and Drug Administration, Severe acute respiratory syndrome-related coronavirus

The test has been submitted to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and is awaiting approval.

Key Points: 
  • The test has been submitted to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and is awaiting approval.
  • The FDA is currently allowing the test to be made available in the U.S. as the agency reviews its EUA application.
  • The FDA is allowing Clungene SARS-CoV-2 IgG/IgM Rapid Serology Test to be made available under its new policy dated May 4, 2020.
  • Proven Pharma has performed multiple site visits of the Hangzhou Clongene Biotech facilities for quality assurance and supply chain efficiencies.

Nice-Pak Disinfectant Products Demonstrate Efficacy Against Virus Causing COVID-19

Retrieved on: 
Tuesday, July 7, 2020
Hygiene, Public health, Babycare, Disposable products, Personal hygiene products, Toilets, Health, Wet wipe, Prevention, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Disinfectant

9480-5) demonstrated efficacy against SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • 9480-5) demonstrated efficacy against SARS-CoV-2, the virus that causes COVID-19.
  • Nice-Pak's wipes are sold under the Grime Boss brand, as well as many popular private labels.
  • If approved, Nice-Pak will update its products' labels, providing consumers with a proven effective solution to kill the SARS-CoV-2 virus, when used according to label instructions.
  • Nice-Pak produces high demand essential cleaning products including Disinfecting Wipes, Antibacterial Hand Wipes, and Personal Hygiene Wipes.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sorrento Therapeutics, Carnival Corporation, Wells Fargo, and Hebron Technology and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, July 8, 2020
Zoonoses, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Virus, Medicine, Epidemiology, Health

On May 15, 2020, Sorrento announced that it had discovered an antibody that had demonstrated 100% inhibition of SARS-CoV-2 virus infection.

Key Points: 
  • On May 15, 2020, Sorrento announced that it had discovered an antibody that had demonstrated 100% inhibition of SARS-CoV-2 virus infection.
  • On that same day, Defendant Henry Ji, founder and Chief Executive Officer of Sorrento referred to Sorrentos breakthrough as a cure.
  • On this news, Sorrento shares closed at $5.70 per share on May 20, 2020, representing a decline of $4.30, or 43.0%, from the Class Period high.
  • For more information on the Hebron Technology class action go to: https://bespc.com/HEBT
    About Bragar Eagel & Squire, P.C.

SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators

Retrieved on: 
Tuesday, July 7, 2020
Journal of the American College of Cardiology, JACC, Severe acute respiratory syndrome-related coronavirus, Academic journals, Anschutz Medical Campus, Publications, Periodicals

https://doi.org/10.1016/j.jacbts.2020.06.007 was published in JACC: Basic to Translational Science (JBTS), a member of the Journal of the American College of Cardiology (JACC) family of journals.

Key Points: 
  • https://doi.org/10.1016/j.jacbts.2020.06.007 was published in JACC: Basic to Translational Science (JBTS), a member of the Journal of the American College of Cardiology (JACC) family of journals.
  • The paper provides new information on mechanisms involved in host cell binding and entry of the SARS-CoV-2 in the human heart.
  • Moreover, mechanisms or constituents other than ACE2 that could participate in CoV2 host cell binding and internalization had not been previously investigated in remodeled human left ventricles (LVs).
  • The University of Colorado Anschutz Medical Campusis a world-class medical destination at the forefront of transformative science, medicine, education, and patient care.

In Vitro Testing of Innovation Pharmaceuticals’ Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy; Manufacturing Preparation Underway for COVID-19 Clinical Trial

Retrieved on: 
Tuesday, July 7, 2020
Viruses, Medicine, Medical specialties, Zoonoses, Coronaviridae, Animal virology, Autoimmune diseases, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Proctitis, Middle East respiratory syndrome-related coronavirus, Severe acute respiratory syndrome

Regional Biocontainment Laboratory (RBL) and has consistently demonstrated robust in vitro antiviral properties against SARS-CoV-2, the novel coronavirus responsible for COVID-19.

Key Points: 
  • Regional Biocontainment Laboratory (RBL) and has consistently demonstrated robust in vitro antiviral properties against SARS-CoV-2, the novel coronavirus responsible for COVID-19.
  • Brilacidin also appears to be showing greatest efficacy in testing when administered as a pre-treatment (virus pre-incubated with Brilacidin prior to infection), in addition to being present during and post-infection.
  • The higher the SI ratio, the more effective and safe a drug has the potential to be in the clinic.
  • Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS).

Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines

Retrieved on: 
Wednesday, July 8, 2020
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Viruses, Coronaviridae, Animal virology, Zoonoses, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, In Saudi Arabia

Osivax announced today that it has received over EUR 30M in public funding from different sources to support the development of universal vaccines against coronavirus and influenza.

Key Points: 
  • Osivax announced today that it has received over EUR 30M in public funding from different sources to support the development of universal vaccines against coronavirus and influenza.
  • Osivax is deploying the same approach toward a universal coronavirus vaccine to protect against the current virus, SARS-Cov-2, and future coronavirus strains.
  • The European Innovation Council (EIC) has selected Osivax to receive up to EUR 17.5M in blended financing with grant and equity support.
  • Additionally, Bpifrance has pledged EUR 15.1M as part of a Projets Structurants Pour la Comptitivit (PSPC) COVID-19 grant to support Osivax coronavirus vaccine program.

Cerus Corporation Reports Successful Inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma

Retrieved on: 
Tuesday, July 7, 2020
Infectious diseases, Biotechnology, Health, Branches of biology, Transfusion medicine, Medical specialties, Blood products, Hematology, Blood, Platelet, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome

Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for transfusion.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for transfusion.
  • The investigators are currently conducting a subsequent study to assess the ability of the INTERCEPT Blood System to inactivate SARS-CoV-2 in platelet components.
  • Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.